US Stock MarketDetailed Quotes

NONOF NOVO NORDISK A/S

Watchlist
  • 128.460
  • +1.010+0.79%
Trading Mar 28 13:06 ET
573.19BMarket Cap46.59P/E (TTM)

About NOVO NORDISK A/S Company

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv?rd, Denmark.

Company Profile

SymbolNONOF
Company NameNOVO NORDISK A/S
Listing Date07/09/1981
Founded1931
CEOMr. Lars Fruergaard Jorgensen
MarketPink Market
Employees64319
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressNovo Allé 1
CityBagsv?rd
ProvinceCapital Region
CountryDenmark
Zip Code2880
Phone45-44-44-88-88

Company Executives

  • Name
  • Position
  • Salary
  • Lars Fruergaard Jorgensen
  • Chief Executive Officer and President
  • --
  • Karsten Munk Knudsen
  • Executive Vice President and Chief Financial Officer
  • 26.40M
  • Marcus Schindler, PhD
  • Executive Vice President, Research and Early Development and Chief Scientific Officer
  • 23.60M
  • David Moore
  • Executive vice president, Corporate Development
  • 2.20M
  • Maziar Mike Doustdar
  • Executive Vice President, International Operations
  • 2.20M
  • Henrik Ehlers Wulff
  • Executive Vice President, Product Supply, Quality Assurance, Digital Data and IT
  • 25.90M
  • Camilla Sylvest
  • Executive Vice President, Commercial Strategy and Corporate Affairs
  • 23.40M
  • Doug Langa
  • Executive Vice President, North America Operations
  • 2.20M
  • Ludovic Helfgott
  • Executive Vice President, Rare Disease
  • 2.20M
  • Martin Holst Lange
  • Executive Vice President, Development
  • 23.40M
  • Tania Sabroe
  • Executive vice president, People and Organisation
  • 2.20M
  • Helge Lund
  • Chairman of the Board
  • 3.90M
  • Henrik Poulsen
  • Vice Chairman of the Board
  • 2.40M
  • Liselotte Hyveled
  • Director
  • 1.10M
  • Kasim Kutay
  • Director
  • 1.30M
  • Mette Bojer Jensen
  • Director
  • 1.30M
  • Thomas Rantzau
  • Director
  • 1.10M
  • Elisabeth Dahl Christensen
  • Director
  • 1.10M
  • Dr. Martin W. Mackay, PhD
  • Independent Director
  • 1.80M
  • Dr. Sylvie Gregoire,Pharm.D.
  • Independent Director
  • 2.00M
  • Laurence Debroux
  • Independent Director
  • 2.10M
  • Andreas Fibig
  • Independent Director
  • 1.40M
  • Christina Law
  • Independent Director
  • 1.70M

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg